Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed) | RFA CA 20 019

Opportunity Information: Apply for RFA CA 20 019

The Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed) opportunity (RFA-CA-20-019) is a National Cancer Institute (NCI) grant program under the NIH and the broader Innovative Molecular Analysis Technologies (IMAT) Program. It is aimed at funding exploratory, early-stage research projects that create genuinely novel technologies to improve the quality, consistency, and overall usefulness of biospecimens used in cancer research and, where relevant, clinical care. The central problem this FOA targets is that many cancer-relevant measurements can be distorted or lost before analysis even begins, due to pre-analytical variables and degradation events that occur during biospecimen collection, processing, handling, transport, and storage. By focusing on this pre-analytical window, the FOA is trying to reduce avoidable variability that can undermine reproducibility, weaken biomarker studies, and limit the reliability of downstream molecular and cellular assays.

Projects are expected to develop innovative tools, devices, instrumentation, and associated methods that either preserve biospecimen integrity or provide ways to interrogate and verify specimen quality. That can include technologies that protect targeted analytes from degradation (for example, nucleic acids, proteins, metabolites, lipids, circulating tumor DNA, extracellular vesicles, or other clinically and biologically meaningful signals) or technologies that establish objective criteria for quality assessment and quality control. A key emphasis is performance under diverse real-world conditions, meaning applicants should consider practical constraints such as variable time-to-processing, temperature excursions, differences in collection sites, shipping realities, and heterogeneous workflows that commonly occur across clinics and research settings. In other words, the FOA is not just interested in incremental process tweaks; it is looking for enabling technologies that can either stabilize samples in a robust way or accurately report whether a sample remains fit for specific downstream purposes.

The intended impact is broad across the cancer research and care continuum. By reducing pre-analytical variation and improving biospecimen quality, these technologies should help accelerate or strengthen studies in cancer biology, early detection and screening, clinical diagnosis, treatment decision-making, and epidemiology. The FOA also explicitly highlights relevance to cancer health disparities, reflecting the idea that biospecimen quality challenges can be amplified in settings with fewer resources or less standardized infrastructure, and that robust, scalable technologies could help improve equity in research participation and clinical testing reliability.

Mechanistically, this is an R21 funding opportunity, which typically supports exploratory and high-risk, high-reward concepts at an early development stage rather than large, late-stage validation efforts. Clinical trials are not allowed under this FOA, so funded work should focus on technology development and demonstration without conducting a clinical trial as defined by NIH. The opportunity is listed under CFDA 93.394 and is offered as a discretionary grant by the Department of Health and Human Services (HHS), NIH.

Eligibility is broad and includes many organization types that might develop biospecimen technologies, such as public and private institutions of higher education, nonprofits (with or without 501(c)(3) status), for-profit organizations (including small businesses), and multiple levels of government entities (state, county, city/township, special districts), as well as eligible Native American tribal governments and tribal organizations, and public housing authorities/Indian housing authorities. This breadth reflects the FOA's technology-forward focus and the reality that impactful biospecimen innovations can come from academic labs, engineering groups, startups, established companies, and public-sector entities.

Administrative details in the source information indicate the FOA was created on December 4, 2019, with an original closing date of September 29, 2020, and an anticipated number of awards around four. The award ceiling is listed as 0 in the provided data, which usually signals that the ceiling is not specified in that field rather than implying no limit, so applicants typically would rely on the FOA text and standard R21 budget rules for the actual constraints. Overall, the program is best understood as a targeted effort to catalyze new biospecimen science technologies that make cancer research measurements more reliable from the moment a sample is collected, thereby improving the credibility and utility of downstream analyses across many applications.

• The Department of Health and Human Services, National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
• This funding opportunity was created on Dec 04, 2019.
• Applicants must submit their applications by Sep 29, 2020. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 4 candidate(s).
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).

Apply for RFA CA 20 019

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: